In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- Colorado HIV bill could expand access to meds for LGBTQ patientson February 24, 2020 at 6:45 pm
Colorado HIV bill could expand access to meds for LGBTQ patients Providing HIV-prevention medications directly through a pharmacist would give patients a way to access treatments in case the doctor’s ...
- S.Africa ‘Sterilized Pregnant HIV Patients Without Consent’on February 24, 2020 at 4:26 pm
JOHANNESBURG (AFP) — A South African inquiry into the forced sterilization of dozens of HIV-positive pregnant women said Monday that their rights had been breached, and called for government action.
- Shining a Light on Jacksonville’s HIV Epidemicon February 24, 2020 at 2:20 pm
In light of the federal government plan announced in February 2019 to end the HIV epidemic in the U.S., TheBody has created a new series called Eyes on the End. This series will include a snapshot of ...
- Few adolescents with HIV achieve viral suppression within 5 monthson February 24, 2020 at 1:42 pm
Kapogiannis BG, et al. JAIDS. 2020;doi:10.1097/QAL0000000000002308. Just 12% of adolescents with HIV aged between 12 and 24 years achieved viral suppression within 5 months after initiating ART, ...
- South African HIV carriers bullied before giving birth to accept sterilizationon February 24, 2020 at 12:56 pm
Dozens of HIV-positive South African women have been sterilized without consent or after being pressured to agree just before giving birth, sometimes being told while in pain on their way to the ...
- S.African HIV carriers bullied before giving birth to accept sterilisationon February 24, 2020 at 12:41 pm
Dozens of HIV-positive South African women have been sterilised without consent or after being pressured to agree just before giving birth, sometimes being told while in pain on their way to the ...
- Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infectionon February 24, 2020 at 12:06 pm
BALTIMORE--(BUSINESS WIRE)--On February 1, the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and OncoImmune, Inc. launched a new Phase II clinical trial ...
- Ready, Set, PrEP: The battle to end the HIV/AIDS epidemic in New Jerseyon February 24, 2020 at 11:53 am
HIV/AIDS continues to be an epidemic in New Jersey with approximately 37,000 residents living with the virus. But through the program: Ready, Set, PrEP, the federal government is aiming to reduce the ...
- The behavioral, cellular and immune mediators of HIV-1 acquisition: New insights from population geneticson February 24, 2020 at 6:44 am
Millions are exposed to the human immunodeficiency virus type 1 (HIV-1) every year, but not all acquire the virus, suggesting a potential role for host genetics in the moderation of HIV-1 acquisition.
- We now know how much our genes influence the risk of contracting HIVon February 24, 2020 at 6:42 am
You might think a person’s risk of catching HIV is solely governed by behavioural choices, such as using condoms, and whether someone is exposed to the virus. But genetics also play a role and may ...
via Google News and Bing News